ERBB2 and NRG1 |
erb-b2 receptor tyrosine kinase 2 |
neuregulin 1 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Axon guidance
- PIP3 activates AKT signaling
- GRB7 events in ERBB2 signaling
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Sema4D in semaphorin signaling
- Sema4D induced cell migration and growth-cone collapse
- Innate Immune System
- Signaling by PDGF
- Downregulation of ERBB2:ERBB3 signaling
- Signalling by NGF
- DAP12 interactions
- GAB1 signalosome
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by ERBB4
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- GRB7 events in ERBB2 signaling
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signaling by PDGF
- Downregulation of ERBB2:ERBB3 signaling
- Signalling by NGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by ERBB4
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Nuclear signaling by ERBB4
- SHC1 events in ERBB4 signaling
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- Trastuzumab
- Lapatinib
- ado-trastuzumab emtansine
- Pertuzumab
- Afatinib
|
|
|
|
ERBB2 and SHC1 |
erb-b2 receptor tyrosine kinase 2 |
SHC (Src homology 2 domain containing) transforming protein 1 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Axon guidance
- PIP3 activates AKT signaling
- GRB7 events in ERBB2 signaling
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Sema4D in semaphorin signaling
- Sema4D induced cell migration and growth-cone collapse
- Innate Immune System
- Signaling by PDGF
- Downregulation of ERBB2:ERBB3 signaling
- Signalling by NGF
- DAP12 interactions
- GAB1 signalosome
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by ERBB4
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- Signaling by GPCR
- Signaling by EGFRvIII in Cancer
- Platelet Aggregation (Plug Formation)
- SHC1 events in ERBB2 signaling
- IRE1alpha activates chaperones
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- SHC-mediated signalling
- G-protein beta:gamma signalling
- SHC-related events triggered by IGF1R
- Signaling by ERBB4
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- GPCR downstream signaling
- SHC1 events in ERBB4 signaling
- Signalling to RAS
- Signaling by EGFR in Cancer
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Signalling to ERKs
- IGF1R signaling cascade
- XBP1(S) activates chaperone genes
- G beta:gamma signalling through PI3Kgamma
- Unfolded Protein Response (UPR)
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- SHC-mediated signalling
- Integrin alphaIIb beta3 signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- SHC-related events
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- SHC1 events in EGFR signaling
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Constitutive Signaling by EGFRvIII
- SHC activation
|
- Trastuzumab
- Lapatinib
- ado-trastuzumab emtansine
- Pertuzumab
- Afatinib
|
|
|
|
FGF3 and FGFR3 |
fibroblast growth factor 3 |
fibroblast growth factor receptor 3 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Phospholipase C-mediated cascade
- SHC-mediated cascade
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Signaling by FGFR2 mutants
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- PI3K Cascade
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- Activated point mutants of FGFR2
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by FGFR mutants
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- FGFR1b ligand binding and activation
- FGFR ligand binding and activation
- FGFR2b ligand binding and activation
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- IRS-mediated signalling
- FGFR2 ligand binding and activation
- FRS2-mediated cascade
- FGFR1 ligand binding and activation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PI3K Cascade
|
- Signaling by FGFR in disease
- Signaling by FGFR3 mutants
- Signaling by activated point mutants of FGFR3
- Signaling by FGFR mutants
- t(4;14) translocations of FGFR3
|
|
|
|
|
FGF3 and FGFR2 |
fibroblast growth factor 3 |
fibroblast growth factor receptor 2 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Phospholipase C-mediated cascade
- SHC-mediated cascade
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Signaling by FGFR2 mutants
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- PI3K Cascade
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- Activated point mutants of FGFR2
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by FGFR mutants
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- FGFR1b ligand binding and activation
- FGFR ligand binding and activation
- FGFR2b ligand binding and activation
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- IRS-mediated signalling
- FGFR2 ligand binding and activation
- FRS2-mediated cascade
- FGFR1 ligand binding and activation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PI3K Cascade
|
- Signaling by FGFR2 amplification mutants
- Signaling by FGFR2 mutants
- Signaling by FGFR in disease
- Signaling by FGFR mutants
- Activated point mutants of FGFR2
|
|
- Palifermin
- Thalidomide
- SU4984
- 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine
- Regorafenib
- Ponatinib
|
|
|
FGF4 and FGFR2 |
fibroblast growth factor 4 |
fibroblast growth factor receptor 2 |
- Signaling by the B Cell Receptor (BCR)
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- SHC-mediated cascade
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Signaling by FGFR2 mutants
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- Signaling by activated point mutants of FGFR1
- Signaling by FGFR1 mutants
- PI3K Cascade
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- Activated point mutants of FGFR2
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- FGFR4 ligand binding and activation
- Signaling by EGFR
- Signaling by FGFR3 mutants
- Downstream signal transduction
- Signaling by activated point mutants of FGFR3
- Fc epsilon receptor (FCERI) signaling
- Signaling by FGFR mutants
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- FGFR3c ligand binding and activation
- FGFR1c ligand binding and activation
- FGFR2c ligand binding and activation
- FGFR ligand binding and activation
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- FGFR3 ligand binding and activation
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- FGFR2 ligand binding and activation
- FRS2-mediated cascade
- IRS-mediated signalling
- FGFR1 ligand binding and activation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PI3K Cascade
|
- Signaling by FGFR2 amplification mutants
- Signaling by FGFR2 mutants
- Signaling by FGFR in disease
- Signaling by FGFR mutants
- Activated point mutants of FGFR2
|
|
- Palifermin
- Thalidomide
- SU4984
- 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine
- Regorafenib
- Ponatinib
|
|
|
FGF4 and FGFR3 |
fibroblast growth factor 4 |
fibroblast growth factor receptor 3 |
- Signaling by the B Cell Receptor (BCR)
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- SHC-mediated cascade
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Signaling by FGFR2 mutants
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- Signaling by activated point mutants of FGFR1
- Signaling by FGFR1 mutants
- PI3K Cascade
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- Activated point mutants of FGFR2
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- FGFR4 ligand binding and activation
- Signaling by EGFR
- Signaling by FGFR3 mutants
- Downstream signal transduction
- Signaling by activated point mutants of FGFR3
- Fc epsilon receptor (FCERI) signaling
- Signaling by FGFR mutants
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- FGFR3c ligand binding and activation
- FGFR1c ligand binding and activation
- FGFR2c ligand binding and activation
- FGFR ligand binding and activation
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- FGFR3 ligand binding and activation
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- FGFR2 ligand binding and activation
- FRS2-mediated cascade
- IRS-mediated signalling
- FGFR1 ligand binding and activation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PI3K Cascade
|
- Signaling by FGFR in disease
- Signaling by FGFR3 mutants
- Signaling by activated point mutants of FGFR3
- Signaling by FGFR mutants
- t(4;14) translocations of FGFR3
|
|
|
|
|
FGF6 and FGFR3 |
fibroblast growth factor 6 |
fibroblast growth factor receptor 3 |
- Signaling by the B Cell Receptor (BCR)
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- SHC-mediated cascade
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Signaling by FGFR2 mutants
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- Signaling by activated point mutants of FGFR1
- Signaling by FGFR1 mutants
- PI3K Cascade
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- Activated point mutants of FGFR2
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- FGFR4 ligand binding and activation
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by FGFR mutants
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- FGFR1c ligand binding and activation
- FGFR2c ligand binding and activation
- FGFR ligand binding and activation
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- FGFR2 ligand binding and activation
- FRS2-mediated cascade
- IRS-mediated signalling
- FGFR1 ligand binding and activation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PI3K Cascade
|
- Signaling by FGFR in disease
- Signaling by FGFR3 mutants
- Signaling by activated point mutants of FGFR3
- Signaling by FGFR mutants
- t(4;14) translocations of FGFR3
|
|
|
|
|
FGF6 and FGFR2 |
fibroblast growth factor 6 |
fibroblast growth factor receptor 2 |
- Signaling by the B Cell Receptor (BCR)
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- SHC-mediated cascade
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Signaling by FGFR2 mutants
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- Signaling by activated point mutants of FGFR1
- Signaling by FGFR1 mutants
- PI3K Cascade
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- Activated point mutants of FGFR2
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- FGFR4 ligand binding and activation
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by FGFR mutants
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- FGFR1c ligand binding and activation
- FGFR2c ligand binding and activation
- FGFR ligand binding and activation
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- FGFR2 ligand binding and activation
- FRS2-mediated cascade
- IRS-mediated signalling
- FGFR1 ligand binding and activation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PI3K Cascade
|
- Signaling by FGFR2 amplification mutants
- Signaling by FGFR2 mutants
- Signaling by FGFR in disease
- Signaling by FGFR mutants
- Activated point mutants of FGFR2
|
|
- Palifermin
- Thalidomide
- SU4984
- 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine
- Regorafenib
- Ponatinib
|
|
|
FGF10 and FGFR2 |
fibroblast growth factor 10 |
fibroblast growth factor receptor 2 |
- Signaling by the B Cell Receptor (BCR)
- Regulation of gene expression in early pancreatic precursor cells
- Signaling by FGFR in disease
- Phospholipase C-mediated cascade
- SHC-mediated cascade
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- Signaling by FGFR2 mutants
- DAP12 signaling
- PI3K/AKT activation
- Regulation of beta-cell development
- PI-3K cascade
- PI3K Cascade
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- Activated point mutants of FGFR2
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by FGFR mutants
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- FGFR1b ligand binding and activation
- FGFR ligand binding and activation
- FGFR2b ligand binding and activation
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- IRS-mediated signalling
- FGFR2 ligand binding and activation
- FRS2-mediated cascade
- FGFR1 ligand binding and activation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PI3K Cascade
|
- Signaling by FGFR2 amplification mutants
- Signaling by FGFR2 mutants
- Signaling by FGFR in disease
- Signaling by FGFR mutants
- Activated point mutants of FGFR2
|
|
- Palifermin
- Thalidomide
- SU4984
- 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine
- Regorafenib
- Ponatinib
|
|
|
FGFR3 and FGF23 |
fibroblast growth factor receptor 3 |
fibroblast growth factor 23 |
- Signaling by FGFR in disease
- Signaling by FGFR3 mutants
- Signaling by activated point mutants of FGFR3
- Signaling by FGFR mutants
- t(4;14) translocations of FGFR3
|
- Signaling by the B Cell Receptor (BCR)
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- SHC-mediated cascade
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Signaling by FGFR2 mutants
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- Signaling by activated point mutants of FGFR1
- Signaling by FGFR1 mutants
- PI3K Cascade
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- Activated point mutants of FGFR2
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- FGFR4 ligand binding and activation
- Signaling by EGFR
- Signaling by FGFR3 mutants
- Downstream signal transduction
- Signaling by activated point mutants of FGFR3
- Fc epsilon receptor (FCERI) signaling
- Signaling by FGFR mutants
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- FGFR3c ligand binding and activation
- FGFR1c ligand binding and activation
- FGFR1c and Klotho ligand binding and activation
- FGFR2c ligand binding and activation
- FGFR ligand binding and activation
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- FGFR3 ligand binding and activation
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- Klotho-mediated ligand binding
- FGFR2 ligand binding and activation
- FRS2-mediated cascade
- IRS-mediated signalling
- FGFR1 ligand binding and activation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PI3K Cascade
|
|
|
|
|
FGFR2 and FGF23 |
fibroblast growth factor receptor 2 |
fibroblast growth factor 23 |
- Signaling by FGFR2 amplification mutants
- Signaling by FGFR2 mutants
- Signaling by FGFR in disease
- Signaling by FGFR mutants
- Activated point mutants of FGFR2
|
- Signaling by the B Cell Receptor (BCR)
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- SHC-mediated cascade
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Signaling by FGFR2 mutants
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- Signaling by activated point mutants of FGFR1
- Signaling by FGFR1 mutants
- PI3K Cascade
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- Activated point mutants of FGFR2
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- FGFR4 ligand binding and activation
- Signaling by EGFR
- Signaling by FGFR3 mutants
- Downstream signal transduction
- Signaling by activated point mutants of FGFR3
- Fc epsilon receptor (FCERI) signaling
- Signaling by FGFR mutants
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- FGFR3c ligand binding and activation
- FGFR1c ligand binding and activation
- FGFR1c and Klotho ligand binding and activation
- FGFR2c ligand binding and activation
- FGFR ligand binding and activation
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- FGFR3 ligand binding and activation
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- Klotho-mediated ligand binding
- FGFR2 ligand binding and activation
- FRS2-mediated cascade
- IRS-mediated signalling
- FGFR1 ligand binding and activation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PI3K Cascade
|
- Palifermin
- Thalidomide
- SU4984
- 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine
- Regorafenib
- Ponatinib
|
|
|
|
FOXO3 and SMAD2 |
forkhead box O3 |
SMAD family member 2 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Signaling by NODAL
- Innate Immune System
- Signaling by PDGF
- DAP12 interactions
- Signalling by NGF
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- AKT phosphorylates targets in the nucleus
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
FOXO3 and SMAD4 |
forkhead box O3 |
SMAD family member 4 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Signaling by NODAL
- Innate Immune System
- Signaling by PDGF
- DAP12 interactions
- Signalling by NGF
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- AKT phosphorylates targets in the nucleus
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by BMP
- Transcriptional regulation of pluripotent stem cells
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
KAT2A and MYC |
K(lysine) acetyltransferase 2A |
v-myc avian myelocytomatosis viral oncogene homolog |
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- RNA Polymerase I Transcription Initiation
- RNA Polymerase I Promoter Clearance
- HATs acetylate histones
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- Pre-NOTCH Transcription and Translation
- Signaling by NOTCH1
- Pre-NOTCH Expression and Processing
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
- Chromatin organization
- RNA Polymerase I Transcription
- Signaling by NOTCH
- Notch-HLH transcription pathway
- NOTCH1 Intracellular Domain Regulates Transcription
- Chromatin modifying enzymes
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
- Loss of Function of TGFBR2 in Cancer
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Signaling by Wnt
- Cyclin E associated events during G1/S transition
- binding of TCF/LEF:CTNNB1 to target gene promoters
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- RNF mutants show enhanced WNT signaling and proliferation
- G1/S Transition
- Signaling by NOTCH1
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Mitotic G1-G1/S phases
- FBXW7 Mutants and NOTCH1 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Loss of Function of SMAD2/3 in Cancer
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- S Phase
- Cell Cycle, Mitotic
- Loss of Function of TGFBR1 in Cancer
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- TCF dependent signaling in response to WNT
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Cyclin A:Cdk2-associated events at S phase entry
- Signaling by WNT in cancer
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
GSK3A and MYC |
glycogen synthase kinase 3 alpha |
v-myc avian myelocytomatosis viral oncogene homolog |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- XBP1(S) activates chaperone genes
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- IRE1alpha activates chaperones
- PI3K/AKT activation
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Unfolded Protein Response (UPR)
- Innate Immune System
- Signaling by PDGF
- DAP12 interactions
- Signalling by NGF
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- Loss of Function of TGFBR2 in Cancer
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Signaling by Wnt
- Cyclin E associated events during G1/S transition
- binding of TCF/LEF:CTNNB1 to target gene promoters
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- RNF mutants show enhanced WNT signaling and proliferation
- G1/S Transition
- Signaling by NOTCH1
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Mitotic G1-G1/S phases
- FBXW7 Mutants and NOTCH1 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Loss of Function of SMAD2/3 in Cancer
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- S Phase
- Cell Cycle, Mitotic
- Loss of Function of TGFBR1 in Cancer
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- TCF dependent signaling in response to WNT
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Cyclin A:Cdk2-associated events at S phase entry
- Signaling by WNT in cancer
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
GSK3B and MYC |
glycogen synthase kinase 3 beta |
v-myc avian myelocytomatosis viral oncogene homolog |
- Signaling by the B Cell Receptor (BCR)
- Hedgehog 'off' state
- Signaling by FGFR in disease
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Degradation of beta-catenin by the destruction complex
- PI3K/AKT activation
- PI-3K cascade
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- S33 mutants of beta-catenin aren't phosphorylated
- Beta-catenin phosphorylation cascade
- truncations of AMER1 destabilize the destruction complex
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- CRMPs in Sema3A signaling
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- APC truncation mutants have impaired AXIN binding
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Regulation of HSF1-mediated heat shock response
- Cellular response to heat stress
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- TCF dependent signaling in response to WNT
- Signaling by Hedgehog
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- GLI3 is processed to GLI3R by the proteasome
- Degradation of GLI2 by the proteasome
|
- Loss of Function of TGFBR2 in Cancer
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Signaling by Wnt
- Cyclin E associated events during G1/S transition
- binding of TCF/LEF:CTNNB1 to target gene promoters
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- RNF mutants show enhanced WNT signaling and proliferation
- G1/S Transition
- Signaling by NOTCH1
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Mitotic G1-G1/S phases
- FBXW7 Mutants and NOTCH1 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Loss of Function of SMAD2/3 in Cancer
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- S Phase
- Cell Cycle, Mitotic
- Loss of Function of TGFBR1 in Cancer
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- TCF dependent signaling in response to WNT
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Cyclin A:Cdk2-associated events at S phase entry
- Signaling by WNT in cancer
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- SMAD4 MH2 Domain Mutants in Cancer
|
- Lithium
- 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
- I-5
- N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
- Staurosporine
- Indirubin-3\'-Monoxime
- Adenosine-5\'-Diphosphate
- (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
- Alsterpaullone
- Phosphoaminophosphonic Acid-Adenylate Ester
- 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
- 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
- (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
- 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
- N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
|
|
|
|
HRAS and PIK3CA |
Harvey rat sarcoma viral oncogene homolog |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- SHC-mediated cascade
- MEK activation
- FCERI mediated MAPK activation
- CREB phosphorylation through the activation of Ras
- Signaling by EGFRvIII in Cancer
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- p38MAPK events
- EPH-Ephrin signaling
- SOS-mediated signalling
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- SHC-mediated signalling
- Signaling by PDGF
- DAP12 interactions
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Signaling by VEGF
- Signalling to RAS
- Downstream signal transduction
- Signaling by FGFR mutants
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-2 signaling
- Interleukin-3, 5 and GM-CSF signaling
- Frs2-mediated activation
- Transmission across Chemical Synapses
- Ras activation uopn Ca2+ infux through NMDA receptor
- Adaptive Immune System
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- Axon guidance
- IRS-mediated signalling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- EPHB-mediated forward signaling
- IRS-related events triggered by IGF1R
- EGFR Transactivation by Gastrin
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- RAF phosphorylates MEK
- Downstream signaling of activated FGFR
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Post NMDA receptor activation events
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- SOS-mediated signalling
- SHC-mediated signalling
- IRS-related events
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- ARMS-mediated activation
- SHC1 events in EGFR signaling
- RAF activation
- IRS-mediated signalling
- FRS2-mediated cascade
- Activation of RAS in B cells
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- Constitutive Signaling by EGFRvIII
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by FGFR1 mutants
- Role of phospholipids in phagocytosis
- Phospholipid metabolism
- Fcgamma receptor (FCGR) dependent phagocytosis
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- G alpha (q) signalling events
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- TCR signaling
- Signaling by Interleukins
- Signaling by VEGF
- Downstream signal transduction
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- G alpha (q) signalling events
- Downstream TCR signaling
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Synthesis of PIPs at the plasma membrane
- IRS-related events triggered by IGF1R
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- G alpha (12/13) signalling events
- PI Metabolism
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- GPVI-mediated activation cascade
- Interleukin receptor SHC signaling
- Signaling by FGFR1 fusion mutants
- Constitutive Signaling by EGFRvIII
- PI3K Cascade
|
- Hexane-1,6-Diol
- Trifluoroethanol
- Guanosine-5\'-Triphosphate
- Guanosine-5\'-Diphosphate
- N,N\'-DIMETHYL-N-(ACETYL)-N\'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
|
|
|
|
HSP90AA1 and MYC |
heat shock protein 90kDa alpha (cytosolic), class A member 1 |
v-myc avian myelocytomatosis viral oncogene homolog |
- HSF1 activation
- Regulatory RNA pathways
- Signaling by EGFRvIII in Cancer
- Regulation of PLK1 Activity at G2/M Transition
- Influenza Life Cycle
- Influenza Viral RNA Transcription and Replication
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Uptake and actions of bacterial toxins
- EPH-Ephrin signaling
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Fcgamma receptor (FCGR) dependent phagocytosis
- Recruitment of mitotic centrosome proteins and complexes
- Regulation of actin dynamics for phagocytic cup formation
- vRNP Assembly
- Influenza Infection
- Signaling by ERBB2
- Signaling by VEGF
- Signaling by EGFR in Cancer
- Sema3A PAK dependent Axon repulsion
- Mitotic G2-G2/M phases
- Uptake and function of diphtheria toxin
- PIWI-interacting RNA (piRNA) biogenesis
- Organelle biogenesis and maintenance
- Axon guidance
- Attenuation phase
- G2/M Transition
- VEGFA-VEGFR2 Pathway
- HSF1-dependent transactivation
- EPHA-mediated growth cone collapse
- Metabolism of nitric oxide
- VEGFR2 mediated vascular permeability
- Loss of Nlp from mitotic centrosomes
- Scavenging by Class F Receptors
- eNOS activation and regulation
- Innate Immune System
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Assembly of the primary cilium
- Cellular response to heat stress
- Anchoring of the basal body to the plasma membrane
- Cell Cycle, Mitotic
- eNOS activation
- Loss of proteins required for interphase microtubule organization from the centrosome
- Centrosome maturation
- Constitutive Signaling by EGFRvIII
|
- Loss of Function of TGFBR2 in Cancer
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Signaling by Wnt
- Cyclin E associated events during G1/S transition
- binding of TCF/LEF:CTNNB1 to target gene promoters
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- RNF mutants show enhanced WNT signaling and proliferation
- G1/S Transition
- Signaling by NOTCH1
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Mitotic G1-G1/S phases
- FBXW7 Mutants and NOTCH1 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Loss of Function of SMAD2/3 in Cancer
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- S Phase
- Cell Cycle, Mitotic
- Loss of Function of TGFBR1 in Cancer
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- TCF dependent signaling in response to WNT
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Cyclin A:Cdk2-associated events at S phase entry
- Signaling by WNT in cancer
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- SMAD4 MH2 Domain Mutants in Cancer
|
- Rifabutin
- Nedocromil
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
- Geldanamycin
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
- 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
- 17-Dmag
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
- Adenosine-5\'-Diphosphate
- 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
- 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
- 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
- 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
- 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
- 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
- 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
- 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
- N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
- 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
- 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL
- 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
- 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
- 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
- (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
- 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
- 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
- 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
- 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
- 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
- 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
- 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
- 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
|
|
|
|
KRAS and PIK3CA |
Kirsten rat sarcoma viral oncogene homolog |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- SHC-mediated cascade
- MEK activation
- FCERI mediated MAPK activation
- Signaling by EGFRvIII in Cancer
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Gastrin-CREB signalling pathway via PKC and MAPK
- p38MAPK events
- SOS-mediated signalling
- SHC-mediated signalling
- Signaling by PDGF
- DAP12 interactions
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Signaling by VEGF
- Downstream signal transduction
- Signalling to RAS
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Interleukin-2 signaling
- Frs2-mediated activation
- Signaling by Leptin
- Adaptive Immune System
- Signalling to ERKs
- Prolonged ERK activation events
- Axon guidance
- IRS-mediated signalling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- IRS-related events triggered by IGF1R
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- VEGFR2 mediated cell proliferation
- RAF phosphorylates MEK
- Downstream signaling of activated FGFR
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- SOS-mediated signalling
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- ARMS-mediated activation
- RAF activation
- SHC1 events in EGFR signaling
- IRS-mediated signalling
- Activation of RAS in B cells
- FRS2-mediated cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Constitutive Signaling by EGFRvIII
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by FGFR1 mutants
- Role of phospholipids in phagocytosis
- Phospholipid metabolism
- Fcgamma receptor (FCGR) dependent phagocytosis
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- G alpha (q) signalling events
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- TCR signaling
- Signaling by Interleukins
- Signaling by VEGF
- Downstream signal transduction
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- G alpha (q) signalling events
- Downstream TCR signaling
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Synthesis of PIPs at the plasma membrane
- IRS-related events triggered by IGF1R
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- G alpha (12/13) signalling events
- PI Metabolism
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- GPVI-mediated activation cascade
- Interleukin receptor SHC signaling
- Signaling by FGFR1 fusion mutants
- Constitutive Signaling by EGFRvIII
- PI3K Cascade
|
|
|
|
|
SMAD2 and PIK3CA |
SMAD family member 2 |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by FGFR1 mutants
- Role of phospholipids in phagocytosis
- Phospholipid metabolism
- Fcgamma receptor (FCGR) dependent phagocytosis
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- G alpha (q) signalling events
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- TCR signaling
- Signaling by Interleukins
- Signaling by VEGF
- Downstream signal transduction
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- G alpha (q) signalling events
- Downstream TCR signaling
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Synthesis of PIPs at the plasma membrane
- IRS-related events triggered by IGF1R
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- G alpha (12/13) signalling events
- PI Metabolism
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- GPVI-mediated activation cascade
- Interleukin receptor SHC signaling
- Signaling by FGFR1 fusion mutants
- Constitutive Signaling by EGFRvIII
- PI3K Cascade
|
|
|
|
|